SecSonar.com

EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

EyePoint Pharmaceuticals, Inc. (EYPT) is a Biotechnology company based in US with a market capitalization of $1.2B. Revenue declined 27.5% year-over-year and free cash flow was negative at -$243.4M. This page tracks EYPT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 165 employees · IPO Jan 27, 2005

Valuation

Valuation & price

$12.35 · as of May 17, 2026 · -34.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.76

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.38$13.93$9.49Jul 25Dec 25Jun 26Jul 7, 25$9.49Jul 9, 25$10.96Jul 11, 25$10.36Jul 15, 25$9.84Jul 17, 25$10.30Jul 21, 25$10.54Jul 23, 25$10.70Jul 25, 25$10.48Jul 29, 25$9.85Jul 31, 25$9.82Aug 4, 25$10.06Aug 6, 25$10.58Aug 8, 25$10.23Aug 12, 25$10.75Aug 14, 25$10.85Aug 19, 25$11.04Aug 21, 25$11.60Aug 25, 25$11.59Aug 27, 25$11.84Aug 29, 25$11.57Sep 3, 25$12.00Sep 5, 25$14.01Sep 9, 25$14.19Sep 11, 25$13.33Sep 15, 25$13.41Sep 17, 25$13.64Sep 19, 25$13.25Sep 23, 25$13.39Sep 25, 25$13.19Sep 29, 25$14.05Oct 2, 25$13.50Oct 6, 25$13.62Oct 8, 25$13.88Oct 10, 25$13.57Oct 14, 25$13.16Oct 16, 25$11.55Oct 20, 25$12.03Oct 22, 25$11.45Oct 24, 25$11.98Oct 28, 25$12.25Oct 30, 25$12.21Nov 3, 25$12.45Nov 5, 25$11.02Nov 7, 25$11.21Nov 11, 25$11.65Nov 14, 25$11.58Nov 18, 25$13.96Nov 20, 25$13.64Nov 24, 25$14.40Nov 26, 25$14.79Dec 1, 25$14.26Dec 3, 25$14.52Dec 5, 25$17.74Dec 9, 25$17.08Dec 11, 25$16.10Dec 15, 25$16.40Dec 17, 25$16.66Dec 19, 25$17.43Dec 23, 25$18.38Dec 26, 25$18.29Dec 31, 25$18.27Jan 5, 26$17.43Jan 7, 26$17.37Jan 9, 26$16.23Jan 13, 26$15.93Jan 15, 26$15.84Jan 20, 26$15.54Jan 22, 26$16.34Jan 26, 26$15.45Jan 28, 26$15.04Jan 30, 26$13.52Feb 3, 26$12.80Feb 5, 26$12.73Feb 9, 26$14.07Feb 11, 26$12.85Feb 17, 26$14.91Feb 19, 26$14.70Feb 23, 26$17.07Feb 25, 26$17.76Feb 27, 26$17.56Mar 3, 26$18.32Mar 5, 26$15.76Mar 9, 26$15.67Mar 11, 26$14.92Mar 13, 26$13.20Mar 17, 26$13.90Mar 19, 26$13.79Mar 23, 26$12.83Mar 25, 26$13.05Mar 27, 26$12.50Apr 1, 26$13.02Apr 6, 26$13.11Apr 8, 26$14.17Apr 10, 26$14.19Apr 14, 26$14.34Apr 16, 26$14.81Apr 20, 26$15.07Apr 22, 26$14.24Apr 24, 26$13.77Apr 28, 26$13.47Apr 30, 26$13.20May 4, 26$13.85May 6, 26$13.35May 8, 26$13.66May 12, 26$13.62May 15, 26$12.35May 19, 26$11.82May 21, 26$12.78May 26, 26$13.35May 28, 26$13.50Jun 1, 26$13.15Jun 3, 26$12.34Jun 5, 26$11.78Jun 9, 26$11.77Jun 11, 26$12.50Jun 15, 26$12.08Jun 17, 26$13.15Jun 22, 26$13.73Jun 24, 26$14.40Jun 30, 26$14.43
$9.4952-week range$18.85
Loading valuation history…

Fundamentals

Key fundamentals

$1.2B

Market cap

-27.5%

Revenue growth (YoY)

93.4%

Gross margin

-$243.4M

Free cash flow (USD)

-$285.3M

Net debt

Net cash position

30.1%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.6MFY 2017$7.5MFY 2018$3.0MFY 2019$20.4MFY 2020$34.4MFY 2021$36.9MFY 2022$41.4MFY 2023$46.0MFY 2024$43.3MFY 2025$31.4M
$1.6M$31.4M

Free cash flow by year

2016 → 2025

FY 2016$-16.4MFY 2017$-20.6MFY 2018$-22.0MFY 2019$-56.9MFY 2020$-14.8MFY 2021$-50.3MFY 2022$-67.2MFY 2023$-1.6MFY 2024$-130.3MFY 2025$-243.4M
-$16.4M-$243.4M

Gross margin by year

2021 → 2025

FY 202177.9%FY 202279.9%FY 202389.9%FY 202491.4%FY 202593.4%
77.9%93.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • 8-K eventPositive DSMC RecommendationMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Insider sellInsider Sell $37KRibeiro Ramiro · Chief Medical Officer · $36.6KApr 20, 2026Filing
  • 8-K eventInvestor Presentation PostedApr 13, 2026Filing

Questions

Frequently asked questions

What is EyePoint Pharmaceuticals, Inc.'s market cap?

EyePoint Pharmaceuticals, Inc. (EYPT) has a market capitalization of $1.2B.

What is EYPT's P/E ratio?

A meaningful P/E ratio is not available for EYPT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is EYPT's price-to-book (P/B) ratio?

EYPT trades at 3.76 times book value per share.

Are insiders buying EYPT stock?

SEC Form 4 filings show no open-market insider buys at EyePoint Pharmaceuticals, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

AMLX

Amylyx Pharmaceuticals, Inc.

$1.2B

ABSI

Absci Corporation

$1.1B

OPK

OPKO Health, Inc.

$1.1B

MNKD

MannKind Corporation

$1.2B

AKTS

Aktis Oncology, Inc.

$1.1B

XERS

Xeris Biopharma Holdings, Inc.

$1.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.